Between 2023 and 2033, the drug screening market is projected to expand at a 16.1% CAGR. By 2033, the market is predicted to have grown from US$ 7.3 billion in 2023 to a market share of US$ 32.4 billion.
According to a study report on the drug screening industry, there are an increasing number of people using drugs of all kinds, as well as an increasing number of rehab facilities. Furthermore, new government regulations restricting drug use and trafficking are driving up sales of drug screening tools. Authorities are under pressure to limit drug distribution by drug users who promote violence and drug abuse.
Prescription drug abuse is fueling the demand for drug screening systems.as well as black market sales. Furthermore, there is a growing interest in developing drug screening products that are more efficient and effective. The increased use of recreational drugs among young people is fueling the demand for sophisticated drug screening technologies.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-14265
- More adult people indulging in drug consumption, and Islamic countries banning alcohol consumption is fueling the drug screening market. Furthermore, advanced screening and testing measures are pushing governments to adopt screening equipment.
- Enhancing high-throughput screening to discover early-strange drug discovery is expanding the drug screening market size, while additional high-content screening (HCS) is also contributing to the growth of the market.
- Another factor that fuels the market growth is the adoption of fragment-based drug discovery (FBDD) with the bottom-up approach that works on low-complexity compounds or fragments.
- The advanced offices and corporate structure include drug testing and screening solutions that also help the workforce to be clean and conscious. The governments in some countries also push corporate companies to adopt these measures for drug control.
- The misuse of prescribed drugs and their trafficking has also fueled the demand for different drug control measures, flourishing the drug screening market.
Key Points :
- The United States market leads the space in terms of market share and CAGR. The market is anticipated to cross a value of US$ 11.5 billion by 2033. The regional market is expected to thrive at a CAGR of 15.8% between 2023 and 2033.
- The Chinese drug screening market is another significant market. It thrives at a steady CAGR of 15.4% during the forecast period. The market is likely to reach a value of US$ 2.3 billion by 2033. The prevalence of drug consumption and stringent government policies are fueling the demand for drug screening.
- Rapid testing devices are likely to thrive in the product and service type category due to faster and more efficient drug testing methods. It is expected to thrive at a CAGR of 15.8% during the forecast period.
- The drug testing devices laboratories segment tops the end user tally with a CAGR of 15.4% between 2023 and 2033. The growth is attributed to higher consumption and lack of drug testing equipment in the organizations due to the lower awareness.
Competitive Landscape :
The key players focus on providing drug screening solutions at cheaper prices while making these products portable, efficient, and effective. Key competitors also merge, acquire, and partner with other companies to increase the supply chain and distribution channel. The key players in the market are: Laboratory Corporation of America Holdings, Hoffmann -La Roche Ltd, BioMerieux SA, Bio-Rad Laboratories Inc., Biomedical Diagnostics
Unlock exclusive insights with our expert analysts :
https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-14265
For instance:
- Bio-Rad Laboratories Inc has introduced its Bio-Rad which works on different concepts such as target discovery, lead discovery, preclinical research, and Progress development. This has extended the research and development programs for the brand.
- BioMerieux SA has completed its 60 years in the service. This has resulted in the biomerieux and InDevR partnership of 5 million. This will be the exclusive distributor in Europe of VaxArray.
Key Segments
By Sample Type:
- Urine samples
- Breath Samples
- Oral Fluid Samples
- Hair Samples
- Other Samples
By Product and Service:
- Drug screening
- Analytical Instruments
- Rapid Testing Devices
- Consumables
- Drug Screening Service
By End User:
- Drug Testing Laboratories
- Criminal Justice and Law Enforcement Agencies
- Hospitals
- Drug Treatment Centers
- Individual Users
- Pain Management Centers
- Schools and Colleges
- Workplaces
By Region:
- North America
- Latin America
- Europe
- Asia Pacific (APAC)
- Middle East & Africa (MEA)
Unlock Tailored Insights: Customize Your Report for Maximum Impact :
https://www.futuremarketinsights.com/customization-available/rep-gb-14265
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube